People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Other Technology, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celona, Inc. | — | Other Technology | Series C | $134.8M | $368.8M | 2019 |
| Solid Biosciences Inc. | — | Pharmaceuticals | Series C | $109.2M | $139.4M | 2020 |
| Eidos Therapeutics, Inc. | — | Biotechnology | Series B | $26.0M | $1.0B | 2018 |
| Satsuma Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $12.1M | $375.8M | 2016 |
Rajeev Shah at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rajeev Shah on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Heath Lukatch | 1 | 10 |
| Matthew Howard | 1 | 9 |
| Arif Janmohamed | 1 | 8 |
| Hoyoung Huh | 1 | 7 |
| Vab Goel | 1 | 6 |
| Thomas King | 1 | 6 |
| Adam Stone | 1 | 5 |
| Ian Smith | 1 | 4 |
| Matthew Arnold | 1 | 4 |
| Adam Koppel | 1 | 3 |
| Lynne Sullivan | 1 | 3 |
| MARTIN FREED | 1 | 3 |
| Neil Kumar | 1 | 3 |
| Ilan Ganot | 1 | 3 |
| Eric Aguiar | 1 | 3 |
| Alexandre Villela | 1 | 2 |
| Christine Siu | 1 | 2 |
| Laura Perrone | 1 | 2 |
| Stephen DiPalma | 1 | 2 |
| David Tyronne Howton | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.